2026 Bruce E. Sands: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	108	5874	5518	3148	2920	705	69241

Overview

Bruce E. Sands is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their research primarily spans the field of Medicine, with significant contributions to Biochemistry, Genetics, and Molecular Biology.

The scientist's work focuses extensively on several topics within gastrointestinal and immunological research. These include:

Inflammatory Bowel Disease
Microscopic Colitis
Eosinophilic Esophagitis
Immunodeficiency and Autoimmune Disorders
Helicobacter pylori-related gastroenterology studies
Liver Diseases and Immunity
Chronic Lymphocytic Leukemia Research

The subfields Bruce E. Sands engages with include Genetics, Epidemiology, Surgery, Immunology, and Oncology. This multidisciplinary approach supports a broad understanding of complex diseases and therapeutic strategies.

Frequent publication venues for their work are:

Gastroenterology
The American Journal of Gastroenterology
Journal of Crohn's and Colitis
Inflammatory Bowel Diseases
Clinical Gastroenterology and Hepatology

Collaboration is a notable component of Bruce E. Sands' scientific output, with frequent co-authors including:

Silvio Danese
Laurent Peyrin-Biroulet
William J. Sandborn
Brian G. Feagan
Geert D'Haens

Among key recent publications are:

"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD", 2021, Gastroenterology
"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies", 2023, The Lancet
"Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease", 2020, Gastroenterology
"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial", 2022, The Lancet
"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis", 2023, New England Journal of Medicine

Best Publications

Infliximab for induction and maintenance therapy for ulcerative colitis.

Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch

4536
Citations
Infliximab for the treatment of fistulas in patients with Crohn's disease.

D.H. Present;P.J. Rutgeerts;S.R. Targan;S.B. Hanauer

3464
Citations
The BABAR detector

B. Aubert;A. Bazan;A. Boucham;D. Boutigny

3365
Citations
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

Xochitl C Morgan;Timothy L Tickle;Timothy L Tickle;Harry Sokol;Harry Sokol;Dirk Gevers

3054
Citations
Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer

2736
Citations
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey

2688
Citations
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer

2472
Citations
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

1770
Citations
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Dan Turner;Amanda Ricciuto;Ayanna Lewis;Ferdinando D’Amico

1656
Citations
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber;Bruce E Sands;Steve Lewitzky;Marc Vandemeulebroecke

1619
Citations
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens

1579
Citations
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

William J. Sandborn;Christopher Gasink;Long Long Gao;Marion A. Blank

1287
Citations
ACG Clinical Guideline: Management of Crohn’s Disease in Adults

Gary R Lichtenstein;Edward V Loftus;Kim L Isaacs;Miguel D Regueiro

1181
Citations
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

Jean Frédéric Colombel;Paul Rutgeerts;Walter Reinisch;Dirk Esser

1007
Citations
The safety of vedolizumab for ulcerative colitis and Crohn's disease

Jean Frédéric Colombel;Bruce E. Sands;Paul Rutgeerts;William Sandborn

819
Citations
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

Bruce E. Sands;Brian G. Feagan;Paul Rutgeerts;Jean Frédéric Colombel;Jean Frédéric Colombel

753
Citations
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease

Gary R. Lichtenstein;Songkai Yan;Mohan Bala;Marion Blank

711
Citations
Development of the Crohn's disease digestive damage score, the Lémann score†‡§

Benjamin Pariente;Jacques Cosnes;Silvio Danese;William J. Sandborn

690
Citations
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Simon P L Travis;Dan Schnell;Piotr Krzeski;Maria T Abreu

651
Citations
Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis

Corey A. Siegel;Corey A. Siegel;Sadie M. Marden;Sarah M. Persing;Robin J. Larson

628
Citations

Frequent Co-Authors

William J. Sandborn University of California, San Diego

Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai

Brian G. Feagan University of Western Ontario

Edward V. Loftus Mayo Clinic

Silvio Danese Vita-Salute San Raffaele University

Stephen B. Hanauer Northwestern University

Laurent Peyrin-Biroulet University of Lorraine

Remo Panaccione University of Calgary

Marla Dubinsky Icahn School of Medicine at Mount Sinai

Walter Reinisch Medical University of Vienna

External Links

Personal website of Bruce E. Sands

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible study options, there are several online degrees and career pathways worth exploring. Options such as an online pharmd let you work toward becoming a pharmacist while maintaining your current obligations.

For those interested in administrative roles within healthcare, an health information technology online degree provides training in organizing and managing patient records and health information systems.

If you’re looking to quickly enter the workforce, understanding how much is medical billing and coding school can help you find affordable entry points into the healthcare sector. This pathway can be completed relatively quickly and is in high demand.

Online nursing programs are also available, including some of the most affordable nurse practitioner programs. These enable nurses to further their careers and take on advanced clinical roles without having to relocate.